Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Logos Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
Logos Capital

Logos Capital

Operating

Logos Capital: A fundamental investment fund specializing in biotechnology.

Location
San Francisco, CA, US
Founded
2019
Firm
Compare
Portfolio
Employees
Website

Investments

Silence Therapeutics
Silence Therapeutics
Public

Total Raised

$248.7M

Rounds

6

Post Ipo Equity$120MFebruary 2024
Rapport Therapeutics
Rapport Therapeutics

Total Raised

$250M

Rounds

2

Series B$150MAugust 2023
Septerna
Septerna

Total Raised

$250M

Rounds

2

Series B$150MJuly 2023
Series A$100MJanuary 2022
Boundless Bio
Boundless Bio

Total Raised

$251.4M

Rounds

3

Series C$100MMay 2023
Delcath Systems
Delcath Systems
Public

Total Raised

$269.6M

Rounds

13

Post Ipo Equity$85MMarch 2023
Unicycive Therapeutics
Unicycive Therapeutics
Public

Total Raised

$36.6M

Rounds

4

Post Ipo Equity$30MMarch 2023
Entact Bio
Entact Bio

Total Raised

$120.9M

Rounds

2

Series A$81MDecember 2022
Odyssey Therapeutics
Odyssey Therapeutics

Total Raised

$487M

Rounds

3

Series B$168MOctober 2022
Series A$218MDecember 2021
Elektrofi
Elektrofi

Total Raised

$41.9M

Rounds

3

Series B$40MJune 2022
Grain
Grain

Total Raised

$20M

Rounds

6

Series A$16MApril 2022
Triana Biomedicines
Triana Biomedicines

Total Raised

$160.8M

Rounds

4

Series A$110MApril 2022
Synthego
Synthego

Total Raised

$460.5M

Rounds

9

Series E$200MFebruary 2022
Parse Biosciences
Parse Biosciences

Total Raised

$100M

Rounds

6

Series B$41.5MFebruary 2022
Simcha Therapeutics
Simcha Therapeutics

Total Raised

$65M

Rounds

2

Series B$40MJanuary 2022
Freenome
Freenome

Total Raised

$1.1B

Rounds

8

Series D$300MDecember 2021
Arbor Biotechnologies
Arbor Biotechnologies

Total Raised

$230.6M

Rounds

2

Series B$215MNovember 2021
Quanta Therapeutics
Quanta Therapeutics

Total Raised

$140.7M

Rounds

4

Series C$60MOctober 2021
Cedilla Therapeutics
Cedilla Therapeutics

Total Raised

$138.8M

Rounds

3

Series B$25MOctober 2021
Expansion Therapeutics
Expansion Therapeutics

Total Raised

$142.2M

Rounds

3

Series B$80MSeptember 2021
858 Therapeutics
858 Therapeutics

Total Raised

$80.1M

Rounds

2

Series A$60MSeptember 2021
Alpine Immune Sciences
Alpine Immune Sciences
Acquired

Total Raised

$475.3M

Rounds

8

Post Ipo Equity$91MSeptember 2021
Vanqua Bio
Vanqua Bio

Total Raised

$85M

Rounds

2

Series B$85MSeptember 2021
Obsidian Therapeutics
Obsidian Therapeutics

Total Raised

$164.5M

Rounds

2

Series B$115MSeptember 2021